质量改进项目对糖尿病相关并发症5年风险的模拟研究
该研究在大学医院和安全网卫生系统实施ADA的Diabetes INSIDE质量改进项目,针对HbA1c>8.0%的2型糖尿病患者,评估干预前后临床指标变化,并用BRAVO模型模拟5年并发症风险。结果显示QI项目与HbA1c和LDL-C降低相关,并显著降低5年MACE和全因死亡风险。
要点
- QI项目使基线HbA1c>8.0%者HbA1c降低0.84%,LDL-C降低5.94 mg/dL。
- 模拟5年MACE风险RR 0.78,全因死亡风险RR 0.83。
- 基线HbA1c>9.5%者获益更大,MACE风险RR 0.60。
核心结论
- ADA的Diabetes INSIDE质量改进项目可能通过降低HbA1c和LDL-C,显著减少糖尿病相关并发症和死亡风险。
研究设计与样本
- 在Tulane和Parkland两个系统实施为期1年的QI项目,随后6个月评估临床指标。
- 纳入2,429例基线HbA1c>8.0%的个体,使用BRAVO糖尿病模型模拟5年风险。
主要发现
- 基线HbA1c>8.0%者HbA1c降低0.84%,LDL-C降低5.94 mg/dL(均P<0.05)。
- 基线HbA1c>9.5%者HbA1c降低1.67%,LDL-C降低6.81 mg/dL(均P<0.05)。
- 基线HbA1c>8.0%者5年MACE风险RR 0.78(95%CI 0.75-0.81),全因死亡RR 0.83(95%CI 0.82-0.85)。
- 基线HbA1c>9.5%者5年MACE风险RR 0.60(95%CI 0.56-0.65),全因死亡RR 0.61(95%CI 0.59-0.64)。
临床怎么用
- 对血糖控制不佳的2型糖尿病患者,可考虑实施系统级质量改进项目以改善HbA1c和LDL-C。
- QI项目可能带来长期的并发症和死亡风险降低,尤其对基线HbA1c>9.5%者获益更显著。
局限性
- 研究为模拟研究,基于模型假设干预益处持续或每年递减30%,非实际长期随访。
- QI实施周期仅1年,评估期6个月,长期效果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We successfully implemented the American Diabetes Association's (ADA) Diabetes INSIDE (INspiring System Improvement with Data-Driven Excellence) quality improvement (QI) program at a university hospital and safety-net health system (Tulane and Parkland), focused on system-wide improvement in poorly controlled type 2 diabetes (HbA1c >8.0% [64 mmol/mol]). In this study, we estimated the 5-year risk reduction in complications and mortality associated with the QI program. RESEARCH DESIGN AND METHODS: The QI implementation period was 1 year, followed by the postintervention period of 6 months to evaluate the impact of QI on clinical measures. We measured the differences between the baseline and postintervention clinical outcomes in 2,429 individuals with HbA1c >8% (64 mmol/mol) at baseline and used the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes model to project the 5-year risk reduction of diabetes-related complications under the assumption that intervention benefits persist over time. An alternative assumption that intervention benefits diminish by 30% every year was also tested. RESULTS: The QI program was associated with reductions in HbA1c (-0.84%) and LDL cholesterol (LDL-C) (-5.94 mg/dL) among individuals with HbA1c level >8.0% (64 mmol/mol), with greater reduction in HbA1c (-1.67%) and LDL-C (-6.81 mg/dL) among those with HbA1c level >9.5% at baseline (all P < 0.05). The implementation of the Diabetes INSIDE QI program was associated with 5-year risk reductions in major adverse cardiovascular events (MACE) (relative risk [RR] 0.78 [95% CI 0.75-0.81]) and all-cause mortality (RR 0.83 [95% CI 0.82-0.85]) among individuals with baseline HbA1c level >8.0% (64 mmol/mol), and MACE (RR 0.60 [95% CI 0.56-0.65]) and all-cause mortality (RR 0.61 [95% CI 0.59-0.64]) among individuals with baseline HbA1c level >9.5% (80 mmol/mol). Sensitivity analysis also identified a substantially lower risk of diabetes-related complications and mortality associated with the QI program. CONCLUSIONS: Our modeling results suggest that the ADA's Diabetes INSIDE QI program would benefit the patients and population by substantially reducing the 5-year risk of complications and mortality in individuals with diabetes.
引用
- Shao H, Fonseca V, Furman R, et al. Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications: A Simulation Study. Diabetes Care. 2020. PMID: 32887705. doi:10.2337/dc20-0465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。